Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | CVP, Gen. Counsel & Secretary | February 25, 2019 | February 27, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date February 25, 2019 · Filed February 27, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,389 |
Ending reported balance
After 2019-02-26 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2019-02-25 · Exercise / conversion · Acquired 1,156 · Balance 6,918 Row 2 · 2019-02-25 · Sale · Disposed 1,223 · Balance 5,695 F1: Represents the weighted average sales price of the shares sold ranging from a low of $211.00 to a high of $211.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Row 3 · 2019-02-25 · Sale · Disposed 472 · Balance 5,223 Row 4 · 2019-02-26 · Sale · Disposed 834 · Balance 4,389 F2: Represents the weighted average sales price of the shares sold ranging from a low of $208.00 to a high of $208.23 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| Incentive Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.54 · Expires 2025-02-13 | Direct | 708 |
Reported balance
After 2019-02-25 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-02-25 · Exercise / conversion · Disposed 1,156 · Balance 708 F4: Not applicable. F3: Grant of option to buy 3,140 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average sales price of the shares sold ranging from a low of $211.00 to a high of $211.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F2: Represents the weighted average sales price of the shares sold ranging from a low of $208.00 to a high of $208.23 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: Grant of option to buy 3,140 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F4: Not applicable.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akili, Inc.
Report date July 02, 2024 · Filed July 02, 2024
Section 16 reporting ended · disclosed 2024-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-07-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-07-02 · Other · Disposed 30,693 · Balance 92,869 F1: Reflects disposition of shares of common stock (each, a "Share") of the Issuer at a price per Share of $0.4340 (the "Offer Price") pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2024, by and among the Issuer, Virtual Therapeutics Corporation, a Delaware corporation ("Parent") and Alpha Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer, effective as of July 2, 2024 (the "Effective Time") with the Issuer surviving the merger. As of the Effective Time, each Share held by the Reporting Person or her affiliates was converted into the Offer Price. Row 2 · 2024-07-02 · Disposition to issuer · Disposed 92,869 · Balance 0 F2: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share. F3: Reflects disposition of time-based Issuer RSUs pursuant to the terms of the Merger Agreement. Each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into the right to receive a cash payment without interest, less any applicable tax withholding, equal to the Offer Price, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 | Direct | 0 |
Reported balance
After 2024-07-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-07-02 · Disposition to issuer · Disposed 280,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Price was cancelled and converted into the right to receive an amount in cash, without any interest thereon, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Offer Price over the exercise price per Share underlying such Issuer Stock Option by (y) the number of Shares underlying such Issuer Stock Option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of shares of common stock (each, a "Share") of the Issuer at a price per Share of $0.4340 (the "Offer Price") pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2024, by and among the Issuer, Virtual Therapeutics Corporation, a Delaware corporation ("Parent") and Alpha Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer, effective as of July 2, 2024 (the "Effective Time") with the Issuer surviving the merger. As of the Effective Time, each Share held by the Reporting Person or her affiliates was converted into the Offer Price.
F2: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share.
F3: Reflects disposition of time-based Issuer RSUs pursuant to the terms of the Merger Agreement. Each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into the right to receive a cash payment without interest, less any applicable tax withholding, equal to the Offer Price, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal.
F4: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Price was cancelled and converted into the right to receive an amount in cash, without any interest thereon, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Offer Price over the exercise price per Share underlying such Issuer Stock Option by (y) the number of Shares underlying such Issuer Stock Option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2018 Filed Sep 4, 2018 21:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 524 | $254.04 | $133,116.96 |
DisclosureSEC source: 0001567619-18-002057 · doc1.xml · nonDerivative · entry 2 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,239 Read SEC document |
| August 31, 2018 Filed Sep 4, 2018 21:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,129 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-002057 · doc1.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleNon-Qualified Stock Option (right-to-buy) · Derivative | 2,219 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001567619-18-001756 · doc1.xml · derivative · entry 7 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,167 Underlying: Common Stock · 2,219 shares Expires 2027-02-13 F6 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy 10,386 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2018. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 9,400 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-18-001756 · doc1.xml · derivative · entry 6 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,627 Underlying: Common Stock · 9,400 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy 22,027 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2017. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,264 | $245.06 | $799,886.94 |
DisclosureSEC source: 0001567619-18-001756 · doc1.xml · nonDerivative · entry 5 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,634 F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $245.00 to a high of $245.13 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,806 | $244.15 | $685,088.83 |
DisclosureSEC source: 0001567619-18-001756 · doc1.xml · nonDerivative · entry 4 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,898 F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $244.00 to a high of $244.56 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 5,549 | $243.36 | $1,350,399.09 |
DisclosureSEC source: 0001567619-18-001756 · doc1.xml · nonDerivative · entry 3 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,704 F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $243.00 to a high of $243.69 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 2,219 | $141.60 | $314,210.40 |
DisclosureSEC source: 0001567619-18-001756 · doc1.xml · nonDerivative · entry 2 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 9,400 | $67.85 | $637,790.00 |
DisclosureSEC source: 0001567619-18-001756 · doc1.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 21:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 2 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-18-000418 · doc1.xml · derivative · entry 4 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,475 Underlying: Common Stock · 2 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2017. Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 21:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,783 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-18-000418 · doc1.xml · derivative · entry 3 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,512 Underlying: Common Stock · 1,783 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy 3,140 shares of Issuer common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 21:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 2 | $67.85 | $135.70 |
DisclosureSEC source: 0001567619-18-000418 · doc1.xml · nonDerivative · entry 2 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 21:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,783 | $79.54 | $141,819.82 |
DisclosureSEC source: 0001567619-18-000418 · doc1.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2018 Filed Aug 7, 2018 22:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 8,598 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001140361-18-035893 · doc1.xml · derivative · entry 4 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,732 Underlying: Common Stock · 8,598 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy 7,165 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 06, 2018 Filed Aug 7, 2018 22:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,010 | $242.87 | $731,036.89 |
DisclosureSEC source: 0001140361-18-035893 · doc1.xml · nonDerivative · entry 3 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,849 F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $242.69 to a high of $243.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 06, 2018 Filed Aug 7, 2018 22:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 5,588 | $242.10 | $1,352,834.12 |
DisclosureSEC source: 0001140361-18-035893 · doc1.xml · nonDerivative · entry 2 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,859 F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $241.55 to a high of $242.51 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 06, 2018 Filed Aug 7, 2018 22:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 8,598 | $79.54 | $683,884.92 |
DisclosureSEC source: 0001140361-18-035893 · doc1.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 24 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2018. Read SEC document |
| May 30, 2018 Filed May 31, 2018 21:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,185 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001140361-18-026604 · doc1.xml · derivative · entry 3 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,295 Underlying: Common Stock · 1,185 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy 3,140 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| May 30, 2018 Filed May 31, 2018 21:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 475 | $209.98 | $99,740.69 |
DisclosureSEC source: 0001140361-18-026604 · doc1.xml · nonDerivative · entry 2 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,825 F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $209.97 to a high of $209.99 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 30, 2018 Filed May 31, 2018 21:44 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,185 | $79.54 | $94,254.90 |
DisclosureSEC source: 0001140361-18-026604 · doc1.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 38 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 30, 2018. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 212 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-008872 · doc1.xml · derivative · entry 10 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,851 Underlying: Common Stock · 212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. F9 · price: Not applicable. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 406 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-008872 · doc1.xml · derivative · entry 9 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,063 Underlying: Common Stock · 406 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. F9 · price: Not applicable. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 346 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-008872 · doc1.xml · derivative · entry 8 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,469 Underlying: Common Stock · 346 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015. F9 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 841 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-008872 · doc1.xml · derivative · entry 7 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,815 Underlying: Common Stock · 841 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2019. F9 · price: Not applicable. F5 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2019. F5 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2019. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 560 | Not disclosed Strike: $178.26 | Not disclosed |
DisclosureSEC source: 0001140361-18-008872 · doc1.xml · derivative · entry 6 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560 Underlying: Common Stock · 560 shares Expires 2028-02-13 F9 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable on the fifth anniversary of the date of grant. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 8,007 | Not disclosed Strike: $178.26 | Not disclosed |
DisclosureSEC source: 0001140361-18-008872 · doc1.xml · derivative · entry 5 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,007 Underlying: Common Stock · 8,007 shares Expires 2028-02-13 F9 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2019. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 298 | $178.26 | $53,121.48 |
DisclosureSEC source: 0001140361-18-008872 · doc1.xml · nonDerivative · entry 4 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,077 F2 · price: Closing price of Issuer's common stock on the NASDAQ market on February 14, 2018. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 212 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-008872 · doc1.xml · nonDerivative · entry 3 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 406 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-008872 · doc1.xml · nonDerivative · entry 2 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 01:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 346 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-008872 · doc1.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 72 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 29, 2017 and December 29, 2017. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 1,129 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-034456 · doc1.xml · derivative · entry 3 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,974 Underlying: Common Stock · 1,129 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: These restricted stock units were granted to the reporting person on September 1, 2014. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. F3 · price: Not applicable. F2 · derivative.exercise_date: These restricted stock units were granted to the reporting person on September 1, 2014. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. F2 · derivative.expiration_date: These restricted stock units were granted to the reporting person on September 1, 2014. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 365 | $154.98 | $56,567.70 |
DisclosureSEC source: 0001140361-17-034456 · doc1.xml · nonDerivative · entry 2 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,339 Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,129 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-034456 · doc1.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 79 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2017 and June 30, 2017. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:22 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 406 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008020 · doc1.xml · derivative · entry 8 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,103 Underlying: Common Stock · 406 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. F7 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:22 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 346 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008020 · doc1.xml · derivative · entry 7 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,509 Underlying: Common Stock · 346 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015. F7 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:22 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 1,059 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008020 · doc1.xml · derivative · entry 6 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,855 Underlying: Common Stock · 1,059 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. F7 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:22 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 706 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001140361-17-008020 · doc1.xml · derivative · entry 5 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 706 Underlying: Common Stock · 706 shares Expires 2027-02-13 F7 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2018. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:22 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 10,386 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001140361-17-008020 · doc1.xml · derivative · entry 4 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,386 Underlying: Common Stock · 10,386 shares Expires 2027-02-13 F7 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2018. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:22 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 273 | $141.60 | $38,656.80 |
DisclosureSEC source: 0001140361-17-008020 · doc1.xml · nonDerivative · entry 3 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,496 F2 · price: Closing price of Issuer's common stock on the NASDAQ market on February 14, 2017. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:22 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 406 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008020 · doc1.xml · nonDerivative · entry 2 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:22 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 346 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008020 · doc1.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 43 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on December 31, 2016. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 22:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 800 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001140361-16-088670 · doc1.xml · derivative · entry 2 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,480 Underlying: Common Stock · 800 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy 3,140 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 22:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 800 | $79.54 | $63,632.00 |
DisclosureSEC source: 0001140361-16-088670 · doc1.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 52 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.